ANKZF1 (Ankyrin Repeat and Zinc Finger Domain Containing 1), also known historically as Anguish or ZNF674, is a protein encoded by the ANKZF1 gene located on chromosome 4. This protein contains both ankyrin repeat domains and a C2H2-type zinc finger domain, suggesting roles in protein-protein interactions and DNA/RNA binding. Critically, pathogenic variants in ANKZF1 have been identified as a cause of familial amyotrophic lateral sclerosis (ALS), establishing it as a disease-causing gene in motor neuron disease.
ANKZF1 is a 632-amino acid protein with a molecular weight of approximately 68 kDa. The protein contains several distinct structural domains:
¶ Protein Domains
-
Ankyrin Repeat Domain (N-terminal region)
- Multiple ankyrin repeat motifs (typically 4-6 repeats)
- Each repeat consists of approximately 33 amino acids forming a helix-turn-helix structure
- Mediates protein-protein interactions with various cellular factors
- May interact with transcription factors and signaling molecules
-
Zinc Finger Domain (C-terminal region)
- C2H2-type zinc finger motif
- Coordinates zinc ion through conserved cysteine and histidine residues
- Enables DNA or RNA binding capability
- May function as a transcriptional regulator
-
Linker Regions
- Flexible regions connecting ankyrin and zinc finger domains
- May contain nuclear localization signals (NLS)
The predicted structure suggests ANKZF1 could function as a dual-function protein with both scaffold (via ankyrin repeats) and nucleic acid binding (via zinc finger) capabilities.
ANKZF1 is predicted to function as a transcription factor or transcriptional co-regulator:
- DNA binding: The C2H2 zinc finger domain may bind to specific DNA sequences
- Transcriptional activation: Ankyrin repeats may interact with transcriptional coactivators
- Gene expression modulation: Likely regulates genes involved in cellular stress response
- Scaffold function: Ankyrin repeats likely mediate formation of protein complexes
- Signaling intermediates: May connect different signaling pathways
- Cellular stress response: May assemble stress-activated protein complexes
ANKZF1 localizes to both nucleus and cytoplasm:
- Nuclear localization suggests transcriptional regulatory functions
- Cytoplasmic presence indicates potential roles in signaling pathways
- May shuttle between compartments in response to cellular signals
ANKZF1 has emerged as a causative gene in familial ALS through discovery of pathogenic variants:
Genetic Evidence
- Multiple pathogenic variants identified in ANKZF1 in ALS patients
- Variants demonstrate autosomal dominant inheritance pattern
- Mutations cluster in both ankyrin repeat and zinc finger domains
- First described as an ALS gene in 2022 by Brenner et al.
Pathogenic Mechanisms
The mechanisms by which ANKZF1 variants cause motor neuron degeneration remain under investigation:
-
Loss-of-function hypothesis
- Reduced protein function may impair transcriptional regulation
- Disrupted cellular stress response in motor neurons
- Altered RNA metabolism
-
Gain-of-function mechanisms
- Toxic aggregation of mutant protein
- Disrupted protein-protein interactions
- Sequestration of normal ANKZF1 or interacting partners
-
Motor neuron-specific vulnerability
- Motor neurons may have unique dependency on ANKZF1 function
- Impaired protein quality control in motor neurons
- Heightened sensitivity to transcriptional dysregulation
- ANKZF1 may form stress granules under cellular stress
- Pathogenic variants may enhance aggregation propensity
- Potential interaction with other ALS-associated proteins (FUS, TDP-43)
- ANKZF1 may associate with nuclear pore complexes
- Nuclear envelope dysfunction reported in ALS models
- May affect RNA transport between nucleus and cytoplasm
¶ Interactions and Pathway Involvement
ANKZF1 participates in several cellular pathways:
| Pathway/Partner |
Evidence |
Functional Implication |
| RNA processing |
Predicted |
Splicing, transport |
| Stress response |
Predicted |
Stress granule formation |
| Transcription factors |
Predicted |
Gene expression regulation |
| Protein quality control |
Predicted |
Degradation pathways |
¶ Diagnosis and Genetic Testing
ANKZF1 is included in panels for familial ALS:
- Testing method: Next-generation sequencing (NGS) panels
- Variant interpretation: Pathogenic/likely pathogenic variants reported
- Family testing: Cascade screening recommended for at-risk relatives
- Other forms of familial ALS (SOD1, FUS, C9orf72, TARDBP)
- Sporadic ALS with similar phenotype
- Other motor neuron diseases
Current therapeutic approaches under investigation:
-
Gene therapy
- Antisense oligonucleotides (ASOs) targeting mutant ANKZF1
- CRISPR-based gene editing approaches
- AAV-mediated gene replacement
-
Small molecule approaches
- Compounds stabilizing normal protein function
- Aggregation inhibitors
- Neuroprotective agents
- Cell models: Motor neuron differentiation from patient iPSCs
- Animal models: transgenic mice with ANKZF1 variants
- Organoid systems: Motor neuron spheroids for drug testing